




## Hawaii ALS and Neuromuscular Center & Neuromuscular Research Unit selected to Investigate Efgartigimod PH20 SC in Adults with Generalized Myasthenia Gravis (gMG) (ADAPT-EARLY)

Myasthenia gravis (MG) is a rare chronic neuromuscular autoimmune disease caused by pathogenic immunoglobulin G (IgG) autoantibodies binding to components of the neuromuscular junction, which impairs neuromuscular transmission. Generalized MG (gMG) is characterized by debilitating exertional muscle fatigue and weakness, resulting in difficulties with mobility, speech and swallowing, ocular motility, and respiration.

The ADAPT-EARLY study evaluates the clinical outcomes of efgartigimod PH20 SC in adults with new-onset generalized myasthenia gravis (gMG). This open-label, prospective, single-group study aims to assess how well efgartigimod works in individuals with gMG symptoms for less than one year. The study will last for approximately 58 weeks for each participant, with a treatment period of 51 weeks.



Efgartigimod is a medication that targets the neonatal Fc receptor (FcRn). It helps reduce the levels of immunoglobulin G (IgG) antibodies, which are believed to play a role in the development of gMG. By blocking FcRn, efgartigimod can prevent the recycling of IgG antibodies, leading to their removal from the body.

### Key Aspects of the Study:

- Participants: Adults with new-onset gMG (symptoms for less than 1 year).
- Treatment: Efgartigimod PH20 SC (subcutaneous injection).
- Study Design: Phase 4, open-label, prospective, single-group, multicenter study.
- Duration: Each participant will be in the study for approximately 58 weeks, with a 51-week treatment period.
- Purpose: To measure how well adults with new-onset gMG respond to efgartigimod PH20 SC treatment.

More information [NIH Info](#) or call *Dedicated Neuromuscular Research Hotline* (808) 564-6141 [Trial Info](#).



### Natalia Gonzalez, MD,

Director of [Hawaii ALS and Neuromuscular Center](#)

Principal investigator [Neuromuscular Research Unit](#), who is dual fellowship trained in Neuromuscular and Neuroimmunology, Clinical Assistant Professor of Medicine (Neurology), University of Hawai`i John Burns School of Medicine.



CLINICAL TRIALS